Achilles Therapeutics (ACHL) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Achilles Therapeutics has reported a cash position of $86.1 million as of September 30, 2024, with an additional $12.8 million received as a cash R&D tax credit in October. The company is seeking strategic options with BofA Securities following the discontinuation of its TIL-based cNeT program. Financial highlights reveal a net loss of $19.6 million for the third quarter, reflecting increased R&D expenses compared to the previous year.
For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.
